| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1048454128 |
| P356 | DOI | 10.2165/00003088-197702010-00003 |
| P953 | full work available at URL | http://link.springer.com/content/pdf/10.2165/00003088-197702010-00003 |
| P698 | PubMed publication ID | 322909 |
| P50 | author | Terrence F. Blaschke | Q46324734 |
| P2860 | cites work | Drug Research | Q10530143 |
| Drug Metabolism and Disposition | Q1261140 | ||
| Journal of Pharmacology and Experimental Therapeutics | Q1500272 | ||
| Pharmacological Reviews | Q2085079 | ||
| Pharmacokinetics of warfarin following intravenous administration to man | Q71843592 | ||
| Reciprocal Relation between Plasma Albumin Level and Hepatic Sulfobromophthalein Removal | Q71844608 | ||
| Relationship of pentazocine plasma levels to pharmacological activity in man | Q72414393 | ||
| The use of antipyrine in the measurement of total body water in man | Q80318811 | ||
| Biochemical studies on chloramphenicol; tissue distribution and excretion studies | Q80360925 | ||
| Paradoxical urinary excretion of D-glucaric acid in acute viral hepatitis | Q28334080 | ||
| Data point weighting in pharmacokinetic analysis: intravenous paracetamol in man | Q33178622 | ||
| The distribution and excretion of phenobarbital | Q33731873 | ||
| Binding of drugs to serum albumin (first of two parts) | Q34082487 | ||
| Lidocaine Pharmacokinetics in Advanced Heart Failure, Liver Disease, and Renal Failure in Humans | Q34216672 | ||
| Clearance concepts in pharmacokinetics | Q34218381 | ||
| The effects of age and liver disease on the disposition and elimination of diazepam in adult man | Q34473755 | ||
| A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol | Q34515217 | ||
| Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery | Q34518893 | ||
| Effect of smoking on theophylline disposition | Q34534103 | ||
| Pharmacokinetics in the aged: A review | Q34685853 | ||
| Use of Clindamycin in Patients with Liver Disease | Q34970372 | ||
| Metabolism of amylobarbitone in patients with chronic liver disease | Q35174112 | ||
| The effect of barbiturates in patients with liver disease | Q35269951 | ||
| Altered Hepatic Blood Flow and Drug Disposition1 | Q35372340 | ||
| Binding of digitoxin and some related cardenolides to human plasma proteins | Q35570511 | ||
| Morphine binding to human plasma proteins | Q39320186 | ||
| Clearance and biologic half-life as indices of intrinsic hepatic metabolism | Q39321643 | ||
| Factors affecting drug metabolism | Q39906393 | ||
| Influence of binding on drug metabolism and distribution | Q39934940 | ||
| Overview of drug-protein binding | Q39934966 | ||
| Liver disease and drug therapy | Q39947640 | ||
| The binding of drugs by plasma proteins | Q39973717 | ||
| Correlation of aryl hydrocarbon hydroxylase activity of human lymphocyte cultures and plasma elimination rates for antipyrine and phenylbutazone | Q40308588 | ||
| Effect of acute viral hepatitis in man on the disposition and elimination of meperidine | Q40312286 | ||
| Drug disposition and liver disease | Q40497025 | ||
| Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow | Q40528649 | ||
| The binding of drugs to plasma proteins from patients with poor renal function | Q40640466 | ||
| Drug dosage in renal disease | Q40640491 | ||
| Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications | Q40640558 | ||
| Plasma and tissue protein binding of drugs in pharmacokinetics | Q40809296 | ||
| Diazepam and paraldehyde for treatment of severe delirium tremens. A controlled trial | Q40898970 | ||
| Normal disposition of oxazepam in acute viral hepatitis and cirrhosis | Q41940395 | ||
| The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic liver disease | Q42100414 | ||
| Clinical toxicity of chloridazepoxide and diazepam in relation to serum albumin concentration: A report from the Boston collaborative drug surveillance Program | Q42236052 | ||
| First-pass metabolism of nortriptyline in man | Q42597560 | ||
| Binding of anilide-type local anesthetics in human plasma. I. Relationships between binding, physicochemical properties, and anesthetic activity. | Q43576895 | ||
| Morphine and phenytoin binding to plasma proteins in renal and hepatic failure | Q43713096 | ||
| The protein binding of some drugs in plasma from patients with alcoholic liver disease | Q43800317 | ||
| Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green | Q43885138 | ||
| Commentary: a physiological approach to hepatic drug clearance | Q43996648 | ||
| Metabolic Interactions Among Environmental Chemicals and Drugs | Q44132869 | ||
| Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin | Q44242122 | ||
| Effects of route of administration and blood flow on hepatic drug elimination | Q44387053 | ||
| Clearance of antipyrine-dependence of quantitative liver function | Q47864473 | ||
| Relationship between theophylline concentration in plasma and saliva of man | Q47871423 | ||
| The interactions of drugs and plasma proteins. | Q47878012 | ||
| Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease | Q47886443 | ||
| Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man. | Q47980851 | ||
| Serum Protein Binding of Erythromycin, Lincomycin, and Clindamycin | Q47990485 | ||
| Plasma Disappearance and Cerebral Effects of Chlorpromazine in Cirrhosis | Q48737301 | ||
| Plasma protein binding of diazepam and tolbutamide in chronic alcoholics. | Q52712237 | ||
| Effect of portacaval shunt on the disposition of drugs with and without first-pass effect | Q52714562 | ||
| Plasma Protein Binding of Thiopental in Patients with Impaired Renal or Hepatic Function | Q52717616 | ||
| Meperidine kinetics in man; Intravenous injection in surgical patients and volunteers | Q52719773 | ||
| The fate of thiopental in man and a method for its estimation in biological material. | Q52783887 | ||
| The binding capacity of albumin and renal disease. | Q53691178 | ||
| Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration | Q53724121 | ||
| Pharmacokinetics of glymidine (glycodiazine) and tolbutamide in acute and chronic liver diseases | Q54026703 | ||
| Pharmacokinetic drug interactions. | Q54080001 | ||
| Pathophysiological Factors Influencing Drug Kinetics | Q54097059 | ||
| Comparative drug elimination capacity in man-glutethimide, amobarbital, antipyrine, and sulfinpyrazone. | Q54340959 | ||
| Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline. | Q54659082 | ||
| Influence of acute viral hepatitis on phenytoin kinetics and protein binding | Q58817425 | ||
| The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat | Q67251918 | ||
| Pharmacokinetics of ampicillin in cirrhosis | Q67273634 | ||
| Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect | Q67462261 | ||
| Pharmacokinetics in the elderly | Q67501334 | ||
| Absolute quinidine bioavailability | Q67785423 | ||
| Decreased drug binding in serum from patients with chronic hepatic disease | Q67826138 | ||
| Plasma protein binding of chlorpromazine | Q68758848 | ||
| The effect of cirrhosis on the disposition and elimination of meperidine in man | Q68803776 | ||
| Metabolism and excretion of digitoxin in man | Q68819368 | ||
| Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis | Q68823026 | ||
| Influence of disease on binding of drugs to plasma proteins | Q69035369 | ||
| Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver | Q69390147 | ||
| Morphine metabolism in man | Q69797517 | ||
| Concentration of propoxyphene in human plasma following oral, intramuscular, and intravenous administration | Q69945055 | ||
| The disposition of propranolol. 8. General implications of the effects of liver blood flow on elimination from the perfused rat liver | Q70043133 | ||
| The binding of paracetamol to plasma proteins of man and pig | Q70044252 | ||
| Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy | Q70086060 | ||
| Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants | Q70560587 | ||
| Plasma protein binding of tricyclic anti-depressants in man | Q71223947 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 32-44 | |
| P577 | publication date | 1977-01-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Protein binding and kinetics of drugs in liver diseases | |
| Protein Binding and Kinetics of Drugs in Liver Diseases | |||
| P478 | volume | 2 |
| Q52703667 | Age- and gender-related differences in diazepam pharmacokinetics. |
| Q38599007 | Aging and determinants of hepatic drug clearance |
| Q51700289 | Altered pharmacokinetics of lignocaine after epidural injection in type II diabetics |
| Q42064238 | An intensive drug monitoring study suggesting possible clinical irrelevance of impaired drug disposition in liver disease |
| Q34109352 | Anaesthesia for liver transplantation in children |
| Q52706260 | Antiarrhythmic drugs: clinical pharmacology and therapeutic uses. |
| Q40326236 | Antibiotics and hepatic disease. |
| Q43229039 | Buspirone pharmacokinetics in patients with cirrhosis |
| Q71294137 | Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokinetic study |
| Q71068626 | Cimetidine kinetics and dynamics in patients with severe liver disease |
| Q40160361 | Clearly There is Intrinsic Value in Intrinsic Clearance |
| Q34184941 | Clinical Pharmacokinetics Pethidine |
| Q39720641 | Clinical Pharmacokinetics of Diazepam |
| Q39780098 | Clinical Pharmacokinetics of Hypolipidaemic Drugs |
| Q40157661 | Clinical Pharmacokinetics of Non-steroidal Anti-inflammatory Drugs |
| Q39773902 | Clinical Pharmacokinetics of Phenylbutazone |
| Q40959038 | Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update |
| Q38631266 | Clinical pharmacokinetics in organ transplant patients |
| Q37368175 | Clinical pharmacokinetics in patients with liver disease |
| Q59525269 | Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease |
| Q40884111 | Clinical pharmacokinetics of newer antibacterial agents in liver disease |
| Q40287722 | Clinical pharmacokinetics of prazosin |
| Q39820091 | Clinical pharmacokinetics of prazosin--1985. |
| Q28282125 | Clinical pharmacokinetics of the depot antipsychotics |
| Q34714607 | Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2. |
| Q40081906 | Clinical relevance of pharmacokinetics |
| Q74637131 | Comparative effects of oxygen supplementation on theophylline and acetaminophen clearance in human cirrhosis |
| Q38675004 | Covalent and noncovalent protein binding of drugs: implications for hepatic clearance, storage, and cell-specific drug delivery |
| Q39894132 | Decreased serum protein binding of glymidine in icteric liver disease and its partial correction with charcoal (author's transl |
| Q72615404 | Digitoxin and its metabolites in patients with liver cirrhosis |
| Q38689435 | Disease states and drug pharmacokinetics |
| Q40098103 | Disease-induced changes in the plasma binding of basic drugs |
| Q37950599 | Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II). |
| Q38243179 | Diseases and Drug Protein Binding |
| Q72681029 | Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses |
| Q52437050 | Disposition of synthetic glucocorticoids I. Pharmacokinetics of dexamethasone in healthy adults |
| Q69959917 | Distribution of sodium valproate in normal whole blood and in blood from patients with renal or hepatic disease |
| Q40153504 | Dose-Dependent Pharmacokinetics: Emphasis on Phase I Metabolism |
| Q40164147 | Drug Administration in Hepatic Disease |
| Q39842386 | Drug Kinetics and Hepatic Blood Flow |
| Q39799042 | Drug Prescribing in Hepatobiliary Disease |
| Q39221790 | Drug kinetics and alcohol ingestion |
| Q42007270 | Drug-binding proteins in liver transplant patients |
| Q40338723 | Drugs as indicators of hepatic function. |
| Q51752279 | Effect of albumin distribution. A simulation analysis of the effect of altered albumin distribution on the apparent volume of distribution and apparent elimination rate constant of drugs. |
| Q40333941 | Effect of cardiopulmonary bypass on the pharmacokinetics of drugs |
| Q77575061 | Effect of hepatic insufficiency on pharmacokinetics and drug dosing |
| Q40104510 | Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs |
| Q58817150 | Effect of liver disease on dose optimization |
| Q41234341 | Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy |
| Q39571577 | Guide to drug dosage in hepatic disease |
| Q39842380 | Hepatic First-pass Metabolism in Liver Disease |
| Q40543728 | Hepatotoxicity in Patients with Liver Disease |
| Q40145607 | Host Factors Influencing the Response to Antimicrobial Agents |
| Q77757451 | Increase in serum carbamazepine concentrations after acute viral hepatitis |
| Q39720658 | Individual Differences in the Disposition of Drugs Metabolised in the Body |
| Q40100611 | Influence of Thyroid Dysfunction on Drug Pharmacokinetics |
| Q40287706 | Influence of age and smoking on drug kinetics in man: studies using model compounds |
| Q35209594 | Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics |
| Q40458397 | Interpretation of Drug Levels: Relevance of Plasma Protein Binding |
| Q45188818 | Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients |
| Q40626160 | Long-term depot antipsychotics. A risk-benefit assessment |
| Q39827568 | Metabolism and transport of amphipathic molecules in analbuminemic rats and human subjects |
| Q35572372 | Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences |
| Q70710447 | Naproxen disposition in patients with alcoholic cirrhosis |
| Q44837287 | Opioids during anesthesia in liver and renal failure |
| Q69426463 | Oral pharmacokinetics and ascitic fluid penetration of ofloxacin in cirrhosis |
| Q34621171 | Pethidine binding in whole blood: methodology and clinical significance |
| Q41572654 | Pharmacokinetic and Clinical Implications of Quinidine Protein Binding |
| Q42208301 | Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study |
| Q40102020 | Pharmacokinetic-pharmacodynamic analyses of antihypertensive drugs, nifedipine and propranolol, in spontaneously hypertensive rats to investigate characteristics of effect and side effects |
| Q34819051 | Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction |
| Q39657128 | Pharmacokinetics and pharmacodynamics in critically ill patients |
| Q40182378 | Pharmacokinetics and toxicity testing |
| Q43817892 | Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients |
| Q89145777 | Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps |
| Q59525256 | Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease |
| Q28328301 | Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration |
| Q40307279 | Pharmacokinetics of drug overdose |
| Q49166524 | Pharmacokinetics of famciclovir in subjects with chronic hepatic disease |
| Q33813315 | Pharmacokinetics of haloperidol: an update |
| Q39168412 | Pharmacokinetics of intravenous anaesthetics: implications for clinical use. |
| Q42596162 | Pharmacokinetics of lorcainide in man: a new antiarrhythmic agent |
| Q71763144 | Pharmacokinetics of prenalterol after single and multiple administration of controlled release tablets to patients with congestive heart failure |
| Q42284748 | Pharmacokinetics of quinine in chronic liver disease |
| Q36897388 | Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction |
| Q69873201 | Pharmacokinetics of tolfenamic acid in patients with cirrhosis of the liver |
| Q58073610 | Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective |
| Q40153516 | Plasma and Tissue Binding Considerations in Drug Disposition |
| Q24542426 | Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease |
| Q69376822 | Plasma protein binding of alpidem in healthy volunteers, in neonates and in liver or renal insufficiency |
| Q34448774 | Plasma protein binding of azapropazone in patients with kidney and liver disease |
| Q39757956 | Plasma protein binding of drugs in the elderly |
| Q34397590 | Plasma protein binding of frusemide in liver disease: effect of hypoalbuminaemia and hyperbilirubinaemia |
| Q38691804 | Population pharmacokinetics of haloperidol in terminally ill adult patients. |
| Q34518336 | Prazosin protein binding in health and disease. |
| Q39622793 | Protein Binding of Coumarin Anticoagulants in Disease States |
| Q71295375 | Protein binding and drug clearance |
| Q39662377 | Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs |
| Q40907238 | Psychopharmacologic issues in organ transplantation. Part I: Pharmacokinetics in organ failure and psychiatric aspects of immunosuppressants and anti-infectious agents |
| Q37625519 | Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity |
| Q37713715 | Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites |
| Q37945595 | Role of haloperidol in palliative medicine: an update |
| Q67007889 | The Influence of Bacillus Piliformis (Tyzzer) Infections on the Reliability of Pharmacokinetic Experiments in Mice |
| Q44411301 | The Influence of Hemorrhagic Shock on Etomidate: A Pharmacokinetic and Pharmacodynamic Analysis |
| Q70791837 | The Pathophysiological Basis of Drug Toxicity |
| Q39654047 | The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients |
| Q52705588 | The disposition kinetics of diazepam in pregnant women at parturition. |
| Q34398214 | The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein |
| Q46484916 | The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor |
| Q73534003 | The effect of the acute-phase response on in vitro drug metabolism and plasma protein binding in the horse |
| Q39656617 | The influence of binding to albumin and alpha 1-acid glycoprotein on the clearance of drugs by the liver |
| Q67415893 | The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration |
| Q34447202 | The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis |
| Q67979399 | The pharmacokinetics of bendazac-lysine and 5-hydroxybendazac, its main metabolite, in patients with hepatic cirrhosis |
| Q52321840 | The pharmacokinetics or oral and intravenous allopurinol and intravenous oxypurinol in the horse. |
| Q47257824 | Theophylline disposition following parenteral feeding of malnourished patients |
| Q47951404 | Therapeutic options for patients with lymphoma and liver dysfunction or failure during mechlorethamine shortage |
| Q69610199 | Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis |
| Q22305835 | Use of Benzodiazepines during Pregnancy, Labour and Lactation, with Particular Reference to Pharmacokinetic Considerations |
| Q40694376 | Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations |
| Q40390197 | Use of psychotropic drugs in patients with HIV infection |
| Q41947254 | Variations in drug free fraction during alcohol withdrawal |
| Q69596882 | [Tryptophan metabolism in liver diseases: a pharmacokinetic and enzymatic study] |
Search more.